Wells Fargo analysts have identified potential for growth in Johnson & Johnson’s pharmaceutical division. They believe there is still room for the company to expand and improve its performance in this sector. This assessment comes as Johnson & Johnson’s stock has been performing well, with the company’s shares up by over 9% this year. Wells Fargo’s positive outlook on Johnson & Johnson is based on the company’s strong product pipeline and promising future prospects.

Read more at Investing.com: Wells Fargo sees ‘room to run’ for Johnson & Johnson, highlights pharma upside